公开(公告)号：US20220184041A1

公开(公告)日：2022-06-16

申请号：US17533592

申请日：2021-11-23

Applicant: Pfizer Inc.

Inventor： Shawn Cabral ,  Daniel Paul Canterbury ,  Robert Lee Dow ,  Andrew Fensome ,  Magdalena Korczynska ,  Sophie Yvette Lavergne ,  Allyn Timothy Londregan ,  Vincent Mascitti ,  David Walter Piotrowski ,  Andre Shavnya ,  Meihua Mike Tu ,  Tao Wang ,  Hanna Maria Wisniewska

IPC: A61K31/428 ,  C07D417/04 ,  C07D513/04 ,  A61K31/437 ,  A61K31/353 ,  A61K31/423 ,  A61K31/415 ,  A61K31/192 ,  A61K31/12 ,  A61K31/7105

Abstract: This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.

公开(公告)号：US10851367B2

公开(公告)日：2020-12-01

申请号：US15347339

申请日：2016-11-09

Applicant: Pfizer Inc. ,  The Regents of the University of California

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Aaron Thuma ,  Jennifer A. Doudna ,  Romain Rouet

IPC: C12N9/22 ,  C12N9/96 ,  C12N15/90 ,  A61K47/54

Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20190321382A1

公开(公告)日：2019-10-24

申请号：US16450649

申请日：2019-06-24

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: A61K31/706 ,  C07D309/14 ,  A61K47/64 ,  A61K31/7008 ,  C07H15/12 ,  C07D493/08 ,  C07H15/26 ,  C07H13/04 ,  C07K5/065 ,  A61K31/7056 ,  A61K38/46 ,  C07H15/08

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US10376531B2

公开(公告)日：2019-08-13

申请号：US16023232

申请日：2018-06-29

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D493/08 ,  A61K31/357 ,  A61K31/706 ,  C07D309/14 ,  C07H13/04 ,  C07H15/26 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/46 ,  C07H15/08 ,  C07H15/12 ,  C07K5/065 ,  A61K47/64

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US20180296585A1

公开(公告)日：2018-10-18

申请号：US16023232

申请日：2018-06-29

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: A61K31/706 ,  C07D309/14 ,  A61K47/64 ,  C07D493/08 ,  C07H15/26 ,  C07H13/04 ,  C07K5/065 ,  A61K31/7056 ,  A61K38/46 ,  C07H15/08 ,  C07H15/12 ,  A61K31/7008

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US09439901B2

公开(公告)日：2016-09-13

申请号：US14535556

申请日：2014-11-07

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K31/155 ,  C07D493/08 ,  A61K31/4985 ,  A61K45/06

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

公开(公告)号：US09308204B2

公开(公告)日：2016-04-12

申请号：US14535630

申请日：2014-11-07

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K31/155 ,  C07D493/08 ,  A61K31/4985 ,  A61K45/06

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Abstract translation: 本文描述了式（A）和（B）的化合物及其用于治疗由钠 - 葡萄糖转运蛋白抑制剂（特别是SGLT2抑制剂）介导的疾病，病症和/或病症的用途。

公开(公告)号：US10039778B2

公开(公告)日：2018-08-07

申请号：US15434508

申请日：2017-02-16

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D493/08 ,  A61K31/35 ,  A61K31/706 ,  C07D309/14 ,  C07H13/04 ,  C07H15/26 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/46 ,  C07H15/08 ,  C07H15/12 ,  C07K5/065 ,  A61K47/64

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

公开(公告)号：US09439902B2

公开(公告)日：2016-09-13

申请号：US14535613

申请日：2014-11-07

Applicant: Pfizer Inc.

Inventor： Vincent Mascitti

IPC: A61K31/357 ,  A61K31/155 ,  C07D493/08 ,  A61K31/4985 ,  A61K45/06

CPC classification number: A61K31/4985 ,  A61K31/155 ,  A61K31/357 ,  A61K45/06 ,  C07D493/08

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

公开(公告)号：US09340553B2

公开(公告)日：2016-05-17

申请号：US14714484

申请日：2015-05-18

Applicant: Pfizer Inc.

Inventor： Spiros Liras ,  Vincent Mascitti ,  Benjamin Thuma

IPC: C07D405/14 ,  C07D493/08 ,  C07D309/14 ,  C07H13/04 ,  C07H15/26

CPC classification number: A61K31/706 ,  A61K31/7008 ,  A61K31/7056 ,  A61K38/465 ,  A61K47/64 ,  C07D309/14 ,  C07D493/08 ,  C07H13/04 ,  C07H15/08 ,  C07H15/12 ,  C07H15/26 ,  C07K5/06078 ,  C12Y301/00 ,  Y02A50/463

Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

Abstract translation: 本文描述了式（A）的化合物及其用于治疗由药物组合物介导的疾病，病症和/或病症及其作为唾液酸糖蛋白受体（ASGPR）靶向剂的用途的用途。